A winding road to recovery from sepsis.

Decoding Sepsis Treatment: Is Early Goal-Directed Therapy Really Outdated?

Elliot Brynn in Health & Wellness November 2026 • 4 min read.

"A closer look at a meta-analysis challenging the gold standard of early goal-directed therapy (EGDT) for septic shock and what it means for patient care."

Sepsis, a life-threatening condition arising from the body's overwhelming response to an infection, demands swift and effective treatment. For years, early goal-directed therapy (EGDT) has been a cornerstone of sepsis management, guiding clinicians to aggressively resuscitate patients in the critical initial hours.

EGDT, championed by a landmark study published in 2001, emphasizes achieving specific targets for vital signs like blood pressure, oxygen saturation, and urine output through the administration of intravenous fluids, vasopressors, and blood transfusions. The goal is to optimize oxygen delivery to vital organs and prevent the downward spiral of septic shock.

However, the medical community is now grappling with a challenge to this long-held standard. A recent meta-analysis, pooling data from multiple clinical trials, suggests that EGDT may not lead to better outcomes compared to more conventional or 'usual' care. This has ignited a debate, prompting healthcare professionals to re-examine the evidence and refine their approach to sepsis management.

AI Search Multiple angles on this topic

Stats & Impact

EGDT and Sepsis Outcomes

Early goal-directed therapy (EGDT) was introduced for severe sepsis and septic shock in 2001. The approach involved adjusting cardiac preload, afterload, and contractility to balance oxygen delivery. Rivers and colleagues reported a significant reduction in mortality through protocolized early resuscitation targeting specific hemodynamic parameters, while later research continued to examine emergency-department-based EGDT protocols and one-year mortality.

Standard Approach

From Protocols to Accepted Care

The original EGDT trial randomly assigned patients arriving at an urban emergency department with severe sepsis or septic shock to six hours of EGDT or standard treatment. Subsequent discussion suggested that the early timing of treatment may be more important than the full EGDT protocol. Later evidence challenged the routine use of invasive EGDT targets and indicated that contemporary standard care was not associated with worse outcomes than goal-directed therapy.

History

The 2001 Turning Point

Sepsis remains a leading cause of morbidity and mortality worldwide and a major challenge in emergency medicine. The introduction of early goal-directed therapy in 2001 transformed sepsis management by promoting protocolized hemodynamic resuscitation during the initial hours of care. The source emphasizes that early recognition and timely intervention are critical determinants of patient outcomes.

The PRISM Meta-Analysis: Challenging the EGDT Paradigm

Published in The New England Journal of Medicine, the Protocolized Resuscitation in Sepsis Meta-Analysis (PRISM) combined individual patient data from three large clinical trials (ARISE, ProCESS, and ProMISe) that compared EGDT to usual care in the treatment of septic shock. These trials, conducted in different countries and healthcare settings, aimed to assess whether EGDT truly improved patient outcomes.

The PRISM meta-analysis concluded that EGDT did not result in a significant reduction in mortality or improvement in other key outcomes, such as organ failure or length of hospital stay, compared to usual care. This finding directly contradicted the earlier evidence that had established EGDT as the gold standard of care.

ARISE (Australasian Resuscitation In Sepsis Evaluation): Conducted in Australia and New Zealand, this trial found no significant difference in mortality between EGDT and usual care.
ProCESS (Protocolized Care for Early Septic Shock): Performed in the United States, this trial also showed no benefit of EGDT compared to usual care.
ProMISe (Protocolised Management in Sepsis): Conducted in the United Kingdom, this trial similarly found no significant difference in outcomes between EGDT and usual care.

AI Search Multiple angles on this topic

Latest Research

Recent Evidence on EGDT

Recent reviews continue to examine EGDT through evidence from the ProCESS, ARISE, and ProMISe trials. An individual-patient-data meta-analysis of these trials has been described as an important model for evaluating early goal-directed therapy for septic shock. Other critical-care literature cites the ineffectiveness of EGDT in discussions of blood-pressure targets and related resuscitation strategies.

The meta-analysis has prompted questions about the true value of EGDT and whether it should remain the default approach to sepsis resuscitation. It's important to understand what "usual care" actually entailed in these trials to fully grasp the implications of these findings.

The Evolving Landscape of Sepsis Management

The PRISM meta-analysis and the subsequent debate highlight the dynamic nature of medical knowledge. While EGDT may not be the universal solution once believed, it has undoubtedly contributed to improvements in sepsis care. The focus is now shifting toward a more individualized approach, tailoring treatment strategies to the specific needs of each patient, and a de-emphasis on CVP monitoring as a singular metric.

What the mortality comparison shows

The reported mortality figures are close, and the confidence intervals include outcomes favoring either group. This comparison does not establish that EGDT lowered mortality relative to usual care at the measured time point.^[1]

The pooled analysis excluded ProCESS’s protocol-based standard-therapy group and reconciled residual differences. That describes how the pooled comparison was assembled, not proof that every difference between the trials disappeared.^[2]

What the comparisons leave unresolved

Because usual-care groups commonly received bundle elements, how much of the similar outcome reflects those shared components rather than the additional EGDT protocol?^{[3] [4]}
How should findings from trials using their own definitions of severe sepsis and septic shock be applied when patient-identification definitions differ?^[5]
What role should fluid-resuscitation guidance give dynamic measures compared with physical examination or static parameters alone?^[4]

Sources

Trial of early, goal-directed resuscitation for septic shock. (pubmed.ncbi.nlm.nih.gov)
Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. (pubmed.ncbi.nlm.nih.gov)
Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE (pmc.ncbi.nlm.nih.gov)
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (pmc.ncbi.nlm.nih.gov)
The Impact of the Location of Sepsis Presentation on Compliance to Centers for Medicare and Medicaid Services ( CMS ) Sepsis Core Measures : A Retrospective Cohort (2018)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

What is sepsis?

Sepsis is a life-threatening condition that arises from the body's overwhelming response to an infection. This means the body's defense mechanisms, meant to fight off the infection, go into overdrive, causing widespread inflammation and damage. Without prompt treatment, sepsis can lead to septic shock, organ failure, and death. The severity of sepsis highlights the urgency required in its management.

What is Early Goal-Directed Therapy (EGDT)?

Early Goal-Directed Therapy (EGDT) is a treatment approach for septic shock that focuses on achieving specific targets for vital signs like blood pressure, oxygen saturation, and urine output. These targets are achieved through the administration of intravenous fluids, vasopressors, and blood transfusions. The goal is to optimize oxygen delivery to vital organs. EGDT became a widely adopted standard of care, particularly after a landmark study published in 2001. However, the recent findings of the PRISM meta-analysis have led to questioning its effectiveness.

What is the PRISM meta-analysis?

The PRISM meta-analysis is a study that combined data from multiple clinical trials (ARISE, ProCESS, and ProMISe) to assess the effectiveness of Early Goal-Directed Therapy (EGDT) compared to usual care in treating septic shock. The analysis included individual patient data from these trials. The conclusion of the PRISM meta-analysis was that EGDT did not show a significant reduction in mortality or improvement in outcomes, such as organ failure or length of hospital stay, compared to usual care. This challenged the previous belief in EGDT as the gold standard.

What were the clinical trials that were part of the PRISM meta-analysis?

The clinical trials included in the PRISM meta-analysis – ARISE, ProCESS, and ProMISe – compared Early Goal-Directed Therapy (EGDT) to usual care. ARISE, conducted in Australia and New Zealand, ProCESS, conducted in the United States, and ProMISe, conducted in the United Kingdom, all compared EGDT to usual care. The term "usual care" refers to the standard practices followed in each setting for treating septic shock, which may have included elements of EGDT but were not as strictly protocolized. The results of these trials, when combined in the meta-analysis, showed no significant benefit of EGDT.

What are the implications of the PRISM meta-analysis findings?

The implications of the PRISM meta-analysis are significant. The findings have ignited a debate within the medical community about the continued use of Early Goal-Directed Therapy (EGDT) as the primary approach to sepsis management. The evidence suggests a shift towards a more individualized approach to treatment, where the specific needs of each patient are considered. This shift also encourages a de-emphasis on a single metric like CVP monitoring. This re-evaluation underscores the dynamic nature of medical knowledge and the importance of continually assessing and refining treatment strategies to improve patient outcomes.